Table 2. Results in Stages III and IV... | American Society of Hematology

Table 2.

Results in Stages III and IV According to Clinical Characteristics

Feature	No. of Patients	5-yr FFS (%)	5-yr Survival (%)	Median Survival (mo)
Age
<60	30	57	82	118
≥60	22	37	31^*	36^*
Ann Arbor Stage
III	29	62	71	135
IV	23	37^†	51^†	60^†
LDH
Low	29	56	71	103
High	23	44	49^†	45^†
Marrow
Negative	34	66	71	140
Positive	18	19^*	41^†	55^†
β2M^‡
<3	32	63	64	90
≥3	8	13^*	19^*	13^*
IPI
Low	17	75	85	115
Low-Int	20	64	68	105
High-Int	13	38	28	35
High	2	0^*	0^*	12^*
Tumor score^‡
<3	29	64	64	99
≥3	11	39^†	33^†	19^†

Feature	No. of Patients	5-yr FFS (%)	5-yr Survival (%)	Median Survival (mo)
Age
<60	30	57	82	118
≥60	22	37	31^*	36^*
Ann Arbor Stage
III	29	62	71	135
IV	23	37^†	51^†	60^†
LDH
Low	29	56	71	103
High	23	44	49^†	45^†
Marrow
Negative	34	66	71	140
Positive	18	19^*	41^†	55^†
β2M^‡
<3	32	63	64	90
≥3	8	13^*	19^*	13^*
IPI
Low	17	75	85	115
Low-Int	20	64	68	105
High-Int	13	38	28	35
High	2	0^*	0^*	12^*
Tumor score^‡
<3	29	64	64	99
≥3	11	39^†	33^†	19^†

Statistically significant adverse features (P < .01).

Statistically significant adverse features (P < .05).

β2M data, and therefore Tumor Score assignment, unavailable for 12 patients.